PAHC

Phibro Animal Health Corporation
NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$1.34B
P/E Ratio
14.09
EPS
$2.34
Beta
0.40
52W High
$59.64
52W Low
$28.04
50-Day MA
$37.14
200-Day MA
$41.20
Dividend Yield
1.36%
Profit Margin
6.67%
Forward P/E
13.83
PEG Ratio
1.68

About Phibro Animal Health Corporation

Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.

Official WebsiteUSAFY End: June

Fundamentals

Revenue (TTM)$1.54B
Gross Profit (TTM)$513.61M
EBITDA$246.48M
Operating Margin13.00%
Return on Equity28.20%
Return on Assets8.44%
Revenue/Share (TTM)$37.99
Book Value$10.29
Price-to-Book3.44
Price-to-Sales (TTM)0.87
EV/Revenue1.391
EV/EBITDA9.09
Quarterly Earnings Growth (YoY)10.80%
Quarterly Revenue Growth (YoY)6.30%
Shares Outstanding$21.11M
Float$20.91M
% Insiders0.88%
% Institutions102.84%

Historical Volatility

HV 10-Day
71.32%
HV 20-Day
55.53%
HV 30-Day
50.11%
HV 60-Day
41.73%
HV Rank
69.8%

Volatility is currently expanding

Analyst Ratings

Consensus ($47.00 target)
1
Strong Buy
2
Hold
1
Strong Sell

Latest News

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 4, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 5, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (83.

Business Wire10/28/2026Neutral
PAHC or SYK: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research10/21/2026Positive
PAHC vs. HAE: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research10/5/2026Positive
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research9/18/2026Positive
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. President & Chief Executive Officer, Daniel Bendheim; Chief Operating Officer, Larry Miller; and Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 15, 2026, at 1:05 PM ET at New York Marriott Marquis in New York. The live audio presentation will be available on the.

Business Wire9/9/2026Neutral
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027. Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025) – Net sales of $396.7 million, an increase of $18.1 million, or 5% – Net income of $21.7 million, an increase of $4.5.

Business Wire8/26/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PAHC and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/7/2026